...
首页> 外文期刊>Hybridoma >A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues.
【24h】

A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues.

机译:一种新型单克隆抗体,用于检测石蜡包埋组织中的叶酸受体α。

获取原文
获取原文并翻译 | 示例
           

摘要

Folate biochemical pathway components such as FR-alpha are determinants of response to novel antifolate drugs such as pemetrexed. Knowledge of their level of expression in tumors will enable their optimal use by identifying potentially responsive subgroups of patients. In spite of its importance in the diagnosis and treatment of cancer, monoclonal antibodies to FR-alpha suitable for immunohistochemical analysis of formalin-fixed and paraffin-embedded biopsy samples, or that can be used for Western blot analysis, are not available. The aim of this study was thus to generate a monoclonal antibody that could be used to detect specific expression of FR-alpha in paraffin-embedded tissues. A 189 amino acid region of the FR-alpha sequence was expressed as a recombinant fusion protein and used as antigen to generate monoclonal antibodies. Studies by ELISA and Western blot identified specific reactivity of the BN3.2 antibody to the recombinant protein and a single 40kD protein in whole cell lysates from cell lines known to express FR-alpha. Immunohistochemical analysis of FR-alpha using hybridoma clone BN3.2 in a panel of normal tissues demonstrated expression limited to ovarian epithelia, placental trophoblasts, and proximal kidney tubules. Analysis of a panel of malignant and benign tissues demonstrated limited expression with variable intensities of staining and patterns of both membrane and cytoplasmic reactivity observed between cases. In the majority of malignant ovarian tumors, high intensity staining was observed, predominantly localized to the plasma membrane. Our results show that clone BN3.2 is a sensitive tool for detection of FR-alpha in paraffin-embedded tissues. This preliminary study also supports its use in immunohistochemical studies to determine the role of FR-alpha as a tumor prognostic marker and a possible therapeutic target.
机译:叶酸生化途径成分(例如FR-α)是对新型抗叶酸药物(如培美曲塞)的反应的决定因素。了解它们在肿瘤中的表达水平将通过鉴定患者潜在的反应亚组而使其得到最佳利用。尽管它在癌症的诊断和治疗中很重要,但尚无适用于福尔马林固定和石蜡包埋的活检样品的免疫组织化学分析或可用于蛋白质印迹分析的FR-α单克隆抗体。因此,本研究的目的是产生一种单克隆抗体,该抗体可用于检测石蜡包埋组织中FR-α的特异性表达。 FR-α序列的189个氨基酸区域被表达为重组融合蛋白,并被用作抗原以产生单克隆抗体。 ELISA和Western blot研究确定了BN3.2抗体对重组蛋白和单个40kD蛋白在已知表达FR-α的细胞系中的特异性反应。使用杂交瘤克隆BN3.2在一组正常组织中对FR-alpha进行免疫组织化学分析,结果表明表达仅限于卵巢上皮细胞,胎盘滋养细胞和近端肾小管。对一组恶性和良性组织的分析表明,在病例之间观察到有限的表达,染色强度的变化以及膜和细胞质反应性的变化。在大多数恶性卵巢肿瘤中,观察到高强度染色,主要集中在质膜上。我们的结果表明,克隆BN3.2是检测石蜡包埋组织中FR-α的灵敏工具。该初步研究还支持其在免疫组织化学研究中的用途,以确定FR-α作为肿瘤预后标志物和可能的治疗靶标的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号